DE602004022506D1 - Bakteriophage zur behandlung von bakteriellen biofilmen - Google Patents

Bakteriophage zur behandlung von bakteriellen biofilmen

Info

Publication number
DE602004022506D1
DE602004022506D1 DE602004022506T DE602004022506T DE602004022506D1 DE 602004022506 D1 DE602004022506 D1 DE 602004022506D1 DE 602004022506 T DE602004022506 T DE 602004022506T DE 602004022506 T DE602004022506 T DE 602004022506T DE 602004022506 D1 DE602004022506 D1 DE 602004022506D1
Authority
DE
Germany
Prior art keywords
bacteriophage
treatment
biofilm
bacteriophages
bacterial biofilms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004022506T
Other languages
English (en)
Inventor
Richard Sharp
Gavin Hughes
A Hart
James Taggart Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Protection Agency
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Publication of DE602004022506D1 publication Critical patent/DE602004022506D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/02Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02003Poly(beta-D-mannuronate) lyase (4.2.2.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10041Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602004022506T 2003-01-10 2004-01-12 Bakteriophage zur behandlung von bakteriellen biofilmen Expired - Lifetime DE602004022506D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300597.2A GB0300597D0 (en) 2003-01-10 2003-01-10 Phage biofilms
PCT/GB2004/000073 WO2004062677A1 (en) 2003-01-10 2004-01-12 Bacteriophage for the treatment of bacterial biofilms

Publications (1)

Publication Number Publication Date
DE602004022506D1 true DE602004022506D1 (de) 2009-09-24

Family

ID=9950965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022506T Expired - Lifetime DE602004022506D1 (de) 2003-01-10 2004-01-12 Bakteriophage zur behandlung von bakteriellen biofilmen

Country Status (6)

Country Link
US (1) US7758856B2 (de)
EP (1) EP1587520B1 (de)
AT (1) ATE439139T1 (de)
DE (1) DE602004022506D1 (de)
GB (1) GB0300597D0 (de)
WO (1) WO2004062677A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570130B1 (de) 2003-07-23 2014-11-26 Biocontrol Limited Bakteriophagen gegen P. aeruginosa enhaltende therapeutische Wirkstoffe
CA2578478A1 (en) * 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
WO2006137847A2 (en) * 2004-09-13 2006-12-28 Trustees Of Boston University Engineered enzymatically active bacteriophages and methods of uses thereof
WO2006095345A2 (en) 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
US7932029B1 (en) * 2006-01-04 2011-04-26 Si Lok Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
KR100781669B1 (ko) 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
US7622293B2 (en) * 2007-06-18 2009-11-24 Intralytix, Inc. Pseudomonas aeruginosa: bacteriophage and uses thereof
US8366652B2 (en) * 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US8734718B2 (en) 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
KR100910961B1 (ko) 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
DK2268142T3 (en) 2007-11-27 2017-05-22 Algipharma As USING ALGINATED OLIGOMERS TO FIGHT BIOFILM
US8153119B2 (en) * 2007-12-18 2012-04-10 Trustees Of Boston University Engineered enzymatically active bacteriophage and methods for dispersing biofilms
US8329889B2 (en) * 2008-02-15 2012-12-11 Trustees Of Boston University In vivo gene sensors
US8889105B2 (en) * 2008-11-28 2014-11-18 Warren H. Finlay Bacteriophage compositions for treatment of bacterial infections
EP2384168B1 (de) 2008-12-04 2014-10-08 Searete LLC Aktiv kontrollierbare sterilisierende erregungsabgabe-implantate
US20110208021A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US20120041287A1 (en) * 2008-12-04 2012-02-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US20110160681A1 (en) * 2008-12-04 2011-06-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters having light removable coatings based on a sensed condition
US20110208026A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US8043613B2 (en) 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
US8377866B2 (en) 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
CN102458474B (zh) 2009-06-03 2014-06-11 阿尔吉法玛公司 使用藻酸盐低聚物和抗生素治疗不动杆菌
EP2473042B1 (de) * 2009-09-02 2017-08-02 Synedgen, Inc. Verfahren und zusammensetzungen zur zersetzung eines biofilms mithilfe von chitosanderivat-komponenten
CN103732235B (zh) * 2010-09-17 2018-01-02 药物技术业制药技术股份有限公司 抗菌噬菌体、噬菌体肽及其使用方法
EP2465926A1 (de) * 2010-12-20 2012-06-20 University College Cork Pseudomonas aeruginosa-Bakteriophage und Verwendungen davon
US20140221308A1 (en) * 2011-07-01 2014-08-07 Synedgen, Inc. Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
WO2014059313A1 (en) 2012-10-12 2014-04-17 Lehigh University Thermally stable enzymes, compositions thereof and methods of using same
DE102013106455A1 (de) * 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Verfahren zur Dekontamination von bakteriologischen Verunreinigungen
JP2017524344A (ja) 2014-06-06 2017-08-31 ザ・ホスピタル・フォー・シック・チルドレンThe Hospital For Sick Children バイオフィルムの阻害及び分散における可溶性細菌及び真菌タンパク質並びに方法並びにそれらの使用
CA2960998A1 (en) 2014-09-11 2016-03-17 Synedgen, Inc. Compositions and methods of use thereof
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CA3026590A1 (fr) 2016-06-08 2017-12-14 Onelife S.A. Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implantation infections
CN112543595B (zh) 2018-05-30 2022-11-01 莫尔豪斯医学院 抗微生物组合物,其制备方法和用途
EP4380586A1 (de) * 2021-08-02 2024-06-12 Armata Pharmaceuticals, Inc. Bakteriophagen mit verbesserter antimikrobieller wirkung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678750A (en) * 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US5032574A (en) 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO1993024513A1 (en) * 1992-05-22 1993-12-09 The Children's Hospital Of Philadelphia Gastrointestinal defensins, cdna sequences and method for the production and use thereof
DE69324918T2 (de) * 1993-02-24 1999-11-11 Gunze Kk Arznei gegen cystische fibrosen
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
EP0925756B8 (de) * 1997-12-25 2008-08-13 Nihon Kohden Corporation Gerät zur Übertragung von biologischen Signalen
ES2252263T3 (es) 2000-07-25 2006-05-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Bacteriofago que tiene una gama de hospedadores multiple.

Also Published As

Publication number Publication date
WO2004062677A9 (en) 2004-10-07
WO2004062677A1 (en) 2004-07-29
EP1587520B1 (de) 2009-08-12
EP1587520A1 (de) 2005-10-26
GB0300597D0 (en) 2003-02-12
US20060140911A1 (en) 2006-06-29
US7758856B2 (en) 2010-07-20
ATE439139T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
ATE439139T1 (de) Bakteriophage zur behandlung von bakteriellen biofilmen
ATE534372T1 (de) Verfahren und zusammensetzungen zur behandlung und prävention von infektionen
ATE513551T1 (de) Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
IL157041A0 (en) Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
ATE481134T1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
DK1663168T3 (da) Nikotinformuleringer og anvendelse deraf
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
WO2007130655A3 (en) Phage derived antimicrobial activities
NO20083245L (no) Sykliske antimikrobielle peptider
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
NZ595252A (en) Biofilm treatment
DE602005013648D1 (de) Behandlung von bakteriellen infektionen
WO2005000878A3 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
MX2022006109A (es) Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa.
ATE296536T1 (de) Nichttoxische beschichtungszusammensetzung, verwendungsverfahren und gegen die anlagerung von biofouling-organismen behandelte gegenstände
RS52511B (en) MACHINE DISINFECTION OF ITEMS
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
MY128739A (en) Compositions and methods for treating bacterial infections
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections

Legal Events

Date Code Title Description
8364 No opposition during term of opposition